Molecure (WAR:MOC) Cyclically Adjusted PS Ratio: (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:MOC Molecure SA WAR:MOC
30 GF Score
Price zł5.80
! 3 Warning Signs
View Full Analysis

What is Molecure Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Molecure  (WAR:MOC) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Molecure Cyclically Adjusted PS Ratio Related Terms


Molecure Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Molecure's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecure Cyclically Adjusted PS Ratio Chart

Molecure Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Molecure Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

WAR:MOC vs VRTX, REGN, ALNY: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Molecure's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecure Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecure's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Molecure's Cyclically Adjusted PS Ratio falls into.


WAR:MOC
30GF Score
Molecure SA WAR:MOC
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Molecure Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Molecure's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec24 is calculated as:

For example, Molecure's adjusted Revenue per Share data for the fiscal year that ended in Dec24 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec24 (Change)*Current CPI (Dec24)
=0/154.6602*154.6602
=0.000

Current CPI (Dec24) = 154.6602.

Molecure Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.000 99.471 0.000
201612 0.001 100.366 0.002
201712 0.000 102.564 0.000
201812 0.000 103.785 0.000
201912 0.000 107.123 0.000
202012 8.869 109.565 12.519
202112 0.000 119.088 0.000
202212 0.000 139.113 0.000
202312 0.000 147.741 0.000
202412 0.000 154.660 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Molecure Business Description

Other Exchanges 1B1:Germany
Address Zwirki i Wigury 101, Warsaw, POL, 02-089
Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.
30GF Score

Get the complete analysis for WAR:MOC

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł5.80
Price